Molecular Insight Pharmaceuticals, a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, has received a 10th extension of its waiver agreement with its bond holders, allowing debt restructuring discussions to continue.
Molecular Insight receives 10th extension of waiver agreement with bond holders